02:02:29 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



News for U:INVVY from 2023-05-04 to 2024-05-03 - 13 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-11 14:43U:INVVYNews ReleaseIndivior Announces Publication Demonstrating that OPVEE(TM) (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone
2024-02-29 02:02U:INVVYNews ReleaseCourt Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation
2024-02-22 02:00U:INVVYNews ReleaseIndivior Announces Q4 / FY 2023 Financial Results
2023-11-09 02:05U:INVVYNews ReleaseIndivior Announces Q3 2023 Financial Results
2023-10-11 16:20U:INVVYNews ReleaseIndivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals
2023-09-26 14:30U:INVVYNews ReleaseIndivior Publishes Real World Data Showing SUBLOCADE ‚ ® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada
2023-08-21 02:02U:INVVYNews ReleaseIndivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims
2023-07-27 02:00U:INVVYNews ReleaseIndivior Announces Q2/H1 2023 Financial Results
2023-06-14 13:53U:INVVYNews ReleaseIndivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence
2023-06-12 02:09U:INVVYNews ReleaseIndivior to Commence Trading on Nasdaq
2023-05-25 09:30U:INVVYNews ReleaseIndivior To Participate In Upcoming Investor Conferences
2023-05-23 12:53U:INVVYNews ReleaseIndivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12th
2023-05-22 19:40U:INVVYNews ReleaseIndivior Announces U.S. Food and Drug Administration Approval of OPVEE ‚ ® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl